Showing results (351-360 of 364) with videos related to

Sort By:
Pageof 37
Plos Pathogens|November 4, 2020
Correction: 15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infectionRobert J Evans, Katherine Pline, Catherine A Loynes, et al.
Plos Pathogens|March 29, 2019
15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infectionRobert J Evans, Katherine Pline, Catherine A Loynes, et al.
Nutrients|July 27, 2022
Vitamin D and the Ability to Produce 1,25(OH)2D Are Critical for Protection from Viral Infection of the LungsJuhi Arora, Devanshi R Patel, McKayla J Nicol, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
The Journal of Trauma and Acute Care Surgery|September 25, 2015
Indications for use of thoracic, abdominal, pelvic, and vascular damage control interventions in trauma patients: A content analysis and expert appropriateness rating studyDerek J Roberts, Niklas Bobrovitz, David A Zygun, et al.
Frontiers in Immunology|November 15, 2021
Macrophage Selenoproteins Restrict Intracellular Replication of Francisella tularensis and Are Essential for Host ImmunityRachel L Markley, Katherine H Restori, Bhuvana Katkere, et al.
Annals of Surgery|October 8, 2015
Indications for Use of Damage Control Surgery in Civilian Trauma Patients: A Content Analysis and Expert Appropriateness Rating StudyDerek J Roberts, Niklas Bobrovitz, David A Zygun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Neuro-Oncology|September 8, 2011
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeuticsKathrin Leppek, Gun Woo Byeon, Wipapat Kladwang, et al.
Pageof 37